New Drug Shows Promising Results Against Pancreatic Cancer

New Drug Shows Promising Results Against Pancreatic Cancer
View on original source
Category: Health
Share
Archive
Like
A new daily pill has shown promising results in early clinical trials for pancreatic cancer, with some patients experiencing significant tumor shrinkage and others showing no detectable signs of the disease on scans. The drug, daraxonrasib, was tested alongside chemotherapy in 61 patients with recently diagnosed advanced pancreatic cancer that had spread to other parts of the body. ALSO READ Results from the Phase I/II trial showed that tumors stopped growing in 90% of participants, while more than 60% experienced tumor shrinkage or disappearance. In around 8% of patients, or approximately one in 12, the cancer became undetectable on CT scans. Researchers followed participants for an average of 18 months. Some patients did not experience a return of their cancer during that period, although doctors say longer studies are needed to determine how long the treatment can control the disease. Cancer Research UK described the findings as the biggest advance in pancreatic cancer treatment in decades. The charity’s Dr. Sam Godfrey said the results were encouraging, adding that the drug had found a way to target mutations previously considered difficult to treat. Daraxonrasib works by targeting RAS mutations, which drive tumor growth and are found in most pancreatic cancers. The treatment blocks these mutations, preventing them from supporting cancer growth. Similar mutations also occur in other cancers, including lung and ovarian cancer, raising the possibility of further research into its use. ALSO READ Dr. Wungki Park of Memorial Sloan Kettering Cancer Center said the early findings showed higher tumor response rates, deeper responses and nearly twice the duration of disease control, which could eventually lead to longer survival. However, doctors have cautioned that the results do not mean the drug is a cure. Cancer can return even when scans show no detectable disease, and further research is needed to establish whether the treatment can produce lasting remission and improve overall survival. Pancreatic cancer remains one of the hardest cancers to treat. It accounts for around 3% of all cancer cases in the United States but causes approximately 8% of cancer deaths, killing about 53,000 people annually. See more ProPakistani stories in Google Search and Top Stories.

(0)Comments

 

A note on cookies

Newshunt uses essential cookies to keep you signed in and to remember your language and country, so the site works the way you expect. With your permission, we'd also like to use analytics cookies to understand how people use Newshunt and improve it over time.

Accepting only affects analytics. To learn more, view our Privacy Policy or Terms & Conditions.